Everbright Futures 1009 Gold Review: Intensified Long-Short Game, Is Gold Rebounding or a Bull Trap?
Overnight, London spot precious metals experienced volatile fluctuations. After a rapid decline in gold prices in the early session, there is a need for an oversold rebound; in addition, a slight pullback in long-term US Treasury yields and the US dollar retreating from its high are providing short-term support for gold prices. Regarding economic data, US initial jobless claims data show that employment resilience remains strong. The Federal Reserve's rate hike expectations for December have not been completely dispelled, so the upside remains limited. In the short term, gold is maintaining a bottom-level consolidation.
On the data front, figures from the US Department of Labor show that for the week ending October 3, initial jobless claims fell to a seasonally adjusted 197,000, lower than the market expectation of 200,000, and have remained near the 57-year low for four consecutive weeks. This indicates the US labor market maintains a certain degree of resilience. Federal Reserve Governor Waller stated that further rate hikes are still needed to push inflation down to the 2% target, but it is not necessary to raise rates at consecutive meetings. He also said the dot plot shows rate cuts only after early 2027 following rate hikes. On the geopolitical front, the Middle East conflict escalated again, briefly driving oil prices sharply higher; however, Trump later said there would be no attack on Iran before the election, easing geopolitical tensions. Gold’s price movement has shown sensitivity to the "inflation-interest rate" transmission chain. Thus, the escalation of Middle East tensions, the strong performance of oil prices, and the continued rise in long-term US Treasury yields and a stronger US dollar have ultimately resulted in gold prices maintaining a slightly weak performance.
Written by: Li Qi
Professional Qualification: F3046227
Trading Advisory Qualification: Z0016145
Editor: Zhu Henan
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
